J Korean Med Sci.  2011 May;26(5):612-618. 10.3346/jkms.2011.26.5.612.

Pseudomonas aeruginosa Bacteremia in Children Over Ten Consecutive Years: Analysis of Clinical Characteristics, Risk Factors of Multi-drug Resistance and Clinical Outcomes

• Yang MA
• Lee J
• Choi EH
• Lee HJ

• KMID: 1777858
• DOI: http://doi.org/10.3346/jkms.2011.26.5.612

Abstract

This study aimed to evaluate the clinical profiles, antibiotic susceptibility, risk factors of multi-drug resistance (MDR) and outcomes of P. aeruginosa bacteremia in children by retrospective methods at a tertiary teaching children's hospital in Seoul, Korea during 2000-2009. A total of 62 episodes were evaluated and 59 patients (95.2%) had underlying diseases. Multivariate analysis demonstrated that an intensive care unit (ICU) stay within the previous one month was the only independent risk factor for MDR P. aeruginosa bacteremia (odds ratio [OR], 6.8; 95% confidence interval [CI], 1.3-35.8, P = 0.023). The overall fatality rate associated with P. aeruginosa bacteremia was 14.5% (9 of 62). The fatality rate in patients with MDR P. aeruginosa was 57.1%, compared with 9.1% in non-MDR patients (OR 13.3; 95% CI 2.3-77.2, P = 0.006). However, the presence of respiratory difficulty was the only independent risk factor for overall fatality associated with P. aeruginosa bacteremia according to multivariate analysis (OR 51.0; 95% CI 7.0-369.0, P < 0.001). A previous ICU stay and presentation with respiratory difficulty were associated with acquisition of MDR P. aeruginosa and a higher fatality rate, respectively. Future efforts should focus on the prevention and treatment of P. aeruginosa bacteremia in high-risk children.

Keyword

Pseudomonas aeruginosa; Bacteremia; Drug Resistance, Multiple, Clinical Outcome

MeSH Terms

Adolescent
Bacteremia/*drug therapy/*epidemiology/microbiology
Child
Child, Preschool
*Drug Resistance, Multiple, Bacterial
Female
Hospitals, Teaching
Humans
Infant
Infant, Newborn
Intensive Care Units, Pediatric
Male
Microbial Sensitivity Tests
Pseudomonas Infections/*drug therapy/*epidemiology/microbiology
Pseudomonas aeruginosa/*drug effects
Republic of Korea/epidemiology
Retrospective Studies
Risk Factors
Treatment Outcome

Reference

1. Pier GB, Ramphal R. Mandell GL, Bennett JE, Dolin R, editors. Pseudomonas aeruginosa. Mandell, Douglas, and Bennett's Principles and Practice of Infectious diseases. 2005. 6th ed. Philadelphia: Churchill Livingstone;2587–2615.

2. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999. 28:1128–1133.

3. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999. 43:1379–1382.

4. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004. 57:112–118.

5. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998. 17:701–708.

6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004. 39:309–317.

7. Hauser AR, Cobb E, Bodi M, Mariscal D, Vallés J, Engel JN, Rello J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med. 2002. 30:521–528.

8. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis. 2001. 183:1767–1774.

9. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000. 160:501–509.

10. Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007. 51:3510–3515.

11. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005. 49:1306–1311.

12. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003. 37:745–751.

13. Fergie JE, Shema SJ, Lott L, Crawford R, Patrick CC. Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome. Clin Infect Dis. 1994. 18:390–394.

14. Grisaru-Soen G, Lerner-Geva L, Keller N, Berger H, Passwell JH, Barzilai A. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors. Pediatr Infect Dis J. 2000. 19:959–963.

15. Huang YC, Lin TY, Wang CH. Community-acquired Pseudomonas aeruginosa sepsis in previously healthy infants and children: analysis of forty-three episodes. Pediatr Infect Dis J. 2002. 21:1049–1052.

16. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, Cellini M, Frenos S, Milano GM, Cappelli B, Licciardello M, Beretta C, Aricò M, Castagnola E. Infection Study Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. 2010. 95:1612–1615.

17. Suárez C, Peña C, Tubau F, Gavaldà L, Manzur A, Dominguez MA, Pujol M, Gudiol F, Ariza J. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect. 2009. 58:285–290.

18. Valoor HT, Singhi S, Jayashree M. Low-dose hydrocortisone in pediatric septic shock: an exploratory study in a third world setting. Pediatr Crit Care Med. 2009. 10:121–125.

19. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002. 46:1481–1491.

20. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009. 49:1–45.

21. Clinical and Laboratory Standards Institute. Document M100-S19. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. 2009. Wayne, PA: Clinical and Laboratory Standards Institute.

22. Johnson LE, D'Agata EM, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, Peleg AY. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009. 11:227–234.

23. Gülay Z, Atay T, Amyes SG. Clonal spread of imipenem-resistant Pseudomonas aeruginosa in the intensive care unit of a Turkish hospital. J Chemother. 2001. 13:546–554.

24. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997. 155:1699–1704.

25. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis. 1994. 170:1622–1625.

26. Tacconelli E, Tumbarello M, Bertagnolio S, Citton R, Spanu T, Fadda G, Cauda R. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis. 2002. 8:220–221.

27. Chen HY, Yuan M, Ibrahim-Elmagboul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 1995. 35:521–534.

28. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. 2003. 47:1681–1688.

29. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, Gatell JM, Soriano E, Jimenez de Anta MT. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996. 156:2121–2126.